The omega-3 lipid 17,18-EEQ sensitizes TRPV1 and TRPA1 in sensory neurons through the prostacyclin receptor (IP)
Sign Up to like & getrecommendations! Published in 2020 at "Neuropharmacology"
DOI: 10.1016/j.neuropharm.2020.107952
Abstract: Oxidized lipids play an important role in pain processing by modulation of the activity of sensory neurons. However, the role of many signalling lipids that do not belong to the classical group of eicosanoids, especially… read more here.
Keywords: trpv1 trpa1; prostacyclin receptor; trpa1 sensory; eeq ... See more keywords
Apolipoprotein E favours the blunting by high‐fat diet of prostacyclin receptor activation in the mouse aorta
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Pharmacology"
DOI: 10.1111/bph.14386
Abstract: NO‐mediated, endothelium‐dependent relaxations of isolated arteries are blunted by ageing and high‐fat diets, as well as by apolipoprotein E deletion. The present study was designed to test the hypothesis that apolipoprotein E deletion impairs endothelium‐dependent… read more here.
Keywords: receptor activation; prostacyclin receptor; high fat; apolipoprotein ... See more keywords
12-HETrE inhibits platelet reactivity and thrombosis in part through the prostacyclin receptor.
Sign Up to like & getrecommendations! Published in 2017 at "Blood advances"
DOI: 10.1182/bloodadvances.2017006155
Abstract: The dihomo-γ-linolenic acid (DGLA)-derived metabolite of 12-lipoxygenase, 12-hydroxy-eicosatrienoic acid (12-HETrE), was recently shown to potently inhibit thrombus formation without prolonging bleeding in murine models. Although 12-HETrE was found to inhibit platelet activation via the Gαs… read more here.
Keywords: receptor; prostacyclin receptor; receptor hetre; antiplatelet effects ... See more keywords
Cefminox, a Dual Agonist of Prostacyclin Receptor and Peroxisome Proliferator-Activated Receptor-Gamma Identified by Virtual Screening, Has Therapeutic Efficacy against Hypoxia-Induced Pulmonary Hypertension in Rats
Sign Up to like & getrecommendations! Published in 2018 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2018.00134
Abstract: Prostacyclin receptor (IP) and peroxisome proliferator-activated receptor-gamma (PPARγ) are both potential targets for treatment of pulmonary arterial hypertension (PAH). Expression of IP and PPARγ decreases in PAH, suggesting that screening of dual agonists of IP… read more here.
Keywords: ppar; prostacyclin; agonist; prostacyclin receptor ... See more keywords